[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"histologically-confirmed-relapsed-or-refractory-b-cell-non-hodgkin-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:histologically-confirmed-relapsed-or-refractory-b-cell-non-hodgkin-lymphoma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100626747","phase-1-a-study-of-torl-5-700-in-relapsedrefractory-non-hodgkins-lymphoma-100626747",false,"NCT07439653","A Study of TORL-5-700 in Relapsed\u002FRefractory Non Hodgkin's Lymphoma","A Phase 1\u002F2, First-in-Human, Open-Label, Multicenter Study of TORL-5-700 as a Monotherapy and in Combination for Participants With Relapsed or Refractory Non-Hodgkin Lymphoma","Inclusion Criteria:\n\n* Confirmed B-NHL, including but not limited to de novo DLBCL; FL, Grades 1 to 3A; MCL; transformed lymphoma (tFL, RT) and FL Grade 3B; MZL and MALT.\n* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.\n* At least 1 measurable lesion per Lugano criteria.\n* Tumor tissue is available.\n* Adequate organ function\n\nExclusion Criteria:\n\n* T-cell lymphoma\n* CLL or SL\n* Burkitt lymphoma and high-grade B-cell lymphoma\n* CNS involvement\n* Peripheral neuropathy \\> Grade 2\n* Uncontrolled medical conditions\n* Viral infections","ALL","18 Years",{"count":19,"type":20},155,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","A Phase 1\u002F2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R\u002FR NHL",[27],"Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","RECRUITING","2026-06-09",{"date":31,"type":32},"2026-06-11","ACTUAL",{"date":34,"type":32},"2026-03-31",{"date":36,"type":20},"2029-09-30",{"name":38,"class":39},"TORL Biotherapeutics, LLC","INDUSTRY",3]